New Delhi: Home-grown COVID-19 vaccine Covaxin has shown to develop long-term antibody and T-cell memory responses 3 months after the shot in Phase-1 trials.
Bharat Biotech said the safety outcome in Phase-2 trial was found to be tolerable and it is expected that the antibodies produced will last for 6 to 12 months.
Memory T cells are antigen-specific T cells that stay in the body for a long term after an infection is eliminated. No serious adverse reaction was observed, the company said in a research paper.
Covaxin, now in Phase-3 trials, was tried on 380 healthy children and adults during the Phase-2 trials. As many as 13,000 volunteers have been recruited for Phase III trials and a total of 26,000 participants across multiple sites will be needed for the trials. AIIMS Delhi is recruiting more volunteers to join the trials.
Also Read: Vaccine To Fight New Coronavirus Strain Can Be Made In 6 Weeks If Required: BioNTech
Bhubaneswar: With the budget session of the Odisha Assembly scheduled to commence on February 13,…
Mumbai: The Jalgaon train accident was the result of a ‘sheer rumour’ about fire spread…
Jammu: After a mysterious illness in Jammu and Kashmir claimed at least 17 lives in…
Sundargarh: In a tragic incident, a 12-year-old girl died after she accidentally consumed rice laced…
New Delhi: On Netaji Subhas Chandra Bose’ birth anniversary, Anita Bose Pfaff, daughter of Netaji…
Bhubaneswar: At least four persons were injured and several vehicles damaged in a series of…
This website uses cookies.
